Where AI Can Safely Take Work Out of Regulatory Change Management

Author

Dr Chinedu Madichie

Service Line

Digital Quality & AI-Enabled Regulatory Operations

Executive Brief

Post-approval Chemistry, Manufacturing, and Controls (CMC) variation workflows present significant operational friction across biopharmaceutical supply chains, driving approval delays of 3 to 5 years across international markets (Deavin et al., 2024). While artificial intelligence (AI) offers transformative potential to streamline these processes, health authorities—including the US FDA, EMA, and European Commission—mandate strict risk-based boundaries, human oversight, and traceability.

At BethAri Limited, our strategic analysis identifies a human-accountable automation model as the premier risk-mitigated strategy. This approach delegates high-volume, repeatable information handling—such as registration tracking, dossier text comparison, and form assembly—to AI, while retaining qualified Regulatory and Quality leaders as accountable owners over change classification, strategy selection, evidence evaluation, and submission approval. By deploying our proprietary screening frameworks and governance models, BethAri Limited enables life science clients to resolve operational friction, safeguard compliance, and accelerate market access.

The Market Challenge

Every marketed pharmaceutical product undergoes continuous lifecycle modifications, including new API suppliers, revised specifications, facilities, and analytical methods. In global markets, post-approval CMC variations require filings, notifications, or approvals across every registered jurisdiction (Ramnarine et al., 2020). Regulatory change management serves as the enterprise workflow linking internal Quality System change controls to multi-national filing, approval, and implementation.

Life science executives face complexity driven by two converging forces:

1. Dynamic Regulatory Frameworks: The EU’s amended Variations Regulation applies since January 2025, with revised Variations Guidelines setting updated classifications since January 2026 (EMA, 2025). Concurrently, agencies are issuing AI control guidance, including the FDA’s draft credibility framework (2025), joint EMA–FDA guiding principles (2026), and draft EU GMP Annex 22 (European Commission, 2025).
2. Enterprise Operational Friction: Life science organizations must locate technical facts across disparate dossier formats, reconcile conflicting national rules, and repeatedly re-author core descriptions into market-specific packages.

Structured content research by Algorri, Cauchon, and Abernathy (2020) characterizes traditional CMC submission prep as an inefficient cycle of manual authoring, editing, and verification. At BethAri Limited, we partner with clients to resolve this friction by establishing structured data architectures and defining precisely where AI can automate tasks without compromising regulatory accountability.

Strategic Insights & Operational Evidence

Through our evaluation of regulatory literature, industry surveys, and agency guidance, BethAri Limited synthesizes four core strategic insights informing AI deployment in CMC change management:

1. Global Disparity as the Primary Operational Bottleneck Industry survey data covering 9 ICH Members and 19 Observers (Deavin et al., 2024, Therapeutic Innovation & Regulatory Science) shows that approval delays of 3 to 5 years stem primarily from divergent national filing rules, unpredictable agency timelines, and inconsistent local classifications. Quality leaders across 20+ biopharmaceutical companies report managing multiple registered process versions simultaneously (Ramnarine et al., 2020; Vinther et al., 2021). Global harmonisation mechanisms under ICH Q12—such as Established Conditions and PACMPs—have seen minimal adoption, with only one country reporting protocol usage (Deavin et al., 2024). Consequently, operational friction remains informational: mapping single manufacturing changes across dozens of national classification schemas.
2. Technological Feasibility vs. Model Reliability Boundaries Research by Ahluwalia et al. (2022) demonstrates that linking source data, repositories, semantic structure, and metadata creates machine-readable content enabling automated authoring. However, empirical studies reveal material reliability constraints in AI reasoning. A 2026 benchmark study by Fu, Chen, and Lu in PLOS ONE evaluated four leading LLMs across 11,444 expert-validated pharmaceutical regulation questions. While models achieved 83% to 86% accuracy, performance dropped by 4.4 to 9.0 percentage points on cross-jurisdictional questions comparing regulatory systems. Crucially, the study identified material errors in 3.6% of sampled outputs (18 of 500) passing an automated LLM quality screen. Furthermore, research by Ji et al. (2023) in ACM Computing Surveys confirms that neural text generators produce fluent content unsupported by source inputs (hallucination)—an unacceptable filing risk. As Lucas, Sousa, and Vitorino (2026) emphasize in The AAPS Journal, robust evidence proving sustained operational gains from AI in regulatory affairs remains limited.
3. Human-Automation Interaction and Cognitive Risks Relying on passive human oversight introduces severe vulnerabilities. Human-factors research by Parasuraman and Manzey (2010) proves that automation bias and complacency cause both expert and novice reviewers to miss automated errors and accept incorrect recommendations. Applying Parasuraman, Sheridan, and Wickens’ (2000) types-and-levels framework, BethAri Limited advises calibrating automation levels against model reliability and error consequences, enforcing active line-by-line verification over passive approval.
4. Converging Health Authority Oversight Mandates Regulators are establishing risk-based control expectations. The FDA’s 2025 draft guidance categorizes AI risk by model influence and decision consequence (FDA, 2025; Goodwin Procter, 2025), while EMA’s 2024 reflection paper requires close human supervision for medicinal product information due to generative AI hallucinations (EMA, 2024). Joint EMA–FDA guiding principles issued in January 2026 emphasize evaluating total human–AI system performance (EMA, 2026; Manufacturing Chemist, 2026). In Europe, draft EU GMP Annex 22 proposes restricting generative AI from critical GMP applications while permitting non-critical use under qualified oversight (European Commission, 2025; Drapeau, 2026). Voluntary standards like NIST AI Risk Management Framework (Tabassi, 2023) similarly advocate governing, mapping, measuring, and managing AI risks in context.

Business Advisory & Client Implications

Based on these findings, BethAri Limited advises life science executives to implement a clear operational boundary separating processing work from decision work within regulatory change management.

Decoupling Processing Work from Decision Work

• Processing Work (High Feasibility, Controlled Risk): Transforms, retrieves, or organizes information without altering regulatory meaning. Examples include identifying affected product registrations, extracting site details, comparing approved text across dossiers, populating application forms, checking completeness, and tracking milestones. These high-volume, low-consequence tasks can be automated safely when anchored to controlled repositories with direct source citations.
• Decision Work (High Consequence, Human Accountability): Determines regulatory assertions, legal commitments, or compliance strategies. Examples include evaluating impact on Established Conditions under ICH Q12, selecting variation categories requiring interpretation, judging evidence sufficiency (comparability, validation, stability), grouping changes, and accepting residual risk under ICH Q9(R1) and ICH Q10. These high-consequence tasks demand expert human ownership.

The Operational Architecture: AI Prepares; Accountable Experts Decide

BethAri Limited structures client workflows around the core principle: “AI prepares and retrieves; accountable experts decide and approve.” AI engines should be restricted to retrieving requirements, mapping change records to dossier sections, flagging inconsistencies, and drafting preliminary rationales from verified source records. Generative models must be anchored strictly via Retrieval-Augmented Generation (RAG) to internal quality documents and official regulatory guidelines. Final interpretation, strategy, and submission authorization must remain strictly with qualified Regulatory and Quality professionals.

Our Core Framework & Actionable Takeaways

To operationalize human-accountable automation, BethAri Limited deploys a proprietary, risk-calibrated workflow evaluation framework. We partner with clients to execute eight actionable steps:

1. End-to-End Workflow Mapping: Map the complete variation workflow from change request to global market approval before selecting tools.
2. Five-Factor Screening Assessment: Evaluate every workflow step using BethAri Limited’s Five-Factor Screening Matrix, scoring each criterion from 0 to 2 (Total Score: 0 to 10).
3. Enforce the Mandatory Hard Gate: Apply our non-negotiable rule—any step carrying high decision consequence (Consequence = 2 in Matrix; Consequence = 3 in Readiness Model) is capped at “AI Retrieves” or “Human-Owned”, regardless of aggregate score.
4. Target Low-Consequence Processing: Prioritize AI for high-volume tasks including registration discovery, dossier comparison, metadata validation, form assembly, and milestone tracking.
5. Restrict AI to Proposal Roles: Limit AI outputs to proposing—never deciding—variation classifications, market impact assessments, and documentation gap analyses.
6. Maintain Accountable Human Control: Retain mandatory human sign-off for regulatory strategy, quality risk acceptance, evidence sufficiency, and final agency submission.
7. Implement Enterprise Governance Controls: Require explicit source provenance citations for all AI outputs, maintain audit trails, enforce version control, monitor reviewer error-catch rates, and establish fallback procedures.
8. Dynamic Re-evaluation & Regulatory Alignment: Re-score automated workflows periodically and following major regulatory updates, such as revised EU Variations Guidelines.

Table 1: BethAri Limited Five-Factor Screening Matrix

Scoring Guidance: 8–10: Controlled Automation Candidate; 5–7: Supervised Pilot; 0–4: Human-Led (AI Retrieval Only).

Table 2: BethAri Limited Decision Gate & Automation Readiness Model

Readiness Formula: Readiness = Friction + Repetition + Verifiability − Decision Consequence − Judgement Depth (Range: −3 to +7).

Table 3: Illustrative Workflow Step Classification

Strategic Outlook & Emerging Horizons

Life science leaders must recognize that current evidence regarding AI in CMC change management remains indirect. No prospective empirical studies evaluate AI performance, error rates, or cycle-time reductions within live variation workflows. Operational friction evidence relies primarily on survey data (Deavin et al., 2024), while AI reasoning benchmarks are limited to multiple-choice tests across restricted jurisdictions (Fu et al., 2026).

Furthermore, screening matrices and readiness models represent strategic heuristics requiring customization to an organization’s product portfolio, data architecture, quality system, and risk tolerance. Regulatory guidance also evolves rapidly; key texts, including FDA’s draft credibility guidance and draft EU GMP Annex 22, remain subject to final revisions.

BethAri Limited actively collaborates with industry consortia and client partners to design prospective validation studies. Future initiatives will measure quantitative performance metrics—including error rates, rework frequency, cycle times, reviewer cognitive burden, and global submission consistency—to refine readiness models and establish validated benchmarks for enterprise AI deployment.

How We Help

AI offers life science organizations a powerful mechanism to eliminate operational friction in regulatory change management, provided deployment is grounded in risk-based governance and human-accountable oversight. Quality standards (ICH Q9(R1), Q10, Q12), regulatory mandates (FDA, EMA, European Commission), and human-factors science converge on a unified conclusion: AI should automate repetitive informational processing, while experienced Regulatory and Quality leaders must retain complete ownership over compliance interpretation and strategy.

How BethAri Limited Empowers Life Science Clients

As a premier strategic consulting partner, BethAri Limited helps biopharmaceutical companies navigate this transformation through four specialized advisory offerings:

1. Regulatory Workflow & Data Readiness Audits: We evaluate client CMC data architectures and workflows to pinpoint high-value targets for structured content management and automated retrieval.
2. Custom AI Governance & Screening Frameworks: We adapt our Five-Factor Matrix and Decision Gate Model to align with your specific product risk profiles and global market footprint.
3. Human-In-The-Loop Workflow Design: We engineer compliant workflows integrating Retrieval-Augmented Generation (RAG) and source citations to mitigate automation bias.
4. Change Management & Strategy Advisory: We assist Regulatory and Quality leadership in establishing validated AI controls, training reviewer personnel, and maintaining alignment with health authority expectations across US, EU, and ICH regions.

Get in touch

If you would like to discuss how these issues apply to your organisation, BethAri would be glad to talk. Contact us to start the conversation.